The purpose of this memorandum is to provide direction regarding the provision of all COVID-19 boosters to employees who have completed the COVID-19 vaccination series as recommended by the Centers for Disease Control and Prevention (CDC).
Vaccine information and availability
At this time, there are no anticipated barriers to procuring adequate supply of vaccine. Please review the information fact sheets below.
- Pfizer Vaccine Fact Sheet – Recipients and Caregivers
- Moderna Vaccine Fact Sheet – Recipients and Caregivers
- Janssen Vaccine Fact Sheet – Recipients and Caregivers
Who
All CDCR and CCHCS employees who have completed the COVID-19 vaccination series are eligible for a booster dose at the appropriate dosing interval. The CDC recommends people aged 18-64 years who are at increased risk for COVID-19 exposure and transmission because of their occupational setting may receive a booster of the COVID- 19 vaccine. This means ALL CDCR/CCHCS employees who have completed the COVID- 19 vaccination series (regardless of manufacturer) are eligible for a booster dose at this time. Some employees have already received a third dose due to being immunocompromised. These individuals who received a third dose may receive a booster six months later.
When
The CDC recommendations for the interval between vaccine series completion and booster is dependent upon which vaccine manufacturer was received for the initial vaccine series. The same product (vaccine manufacturer) that was used for the primary vaccine series may be used for the booster dose. However, employee preference for the booster dose should be considered and honored when supply allows. EHP will post a walk-in vaccine clinic schedule at each institution. Clinic schedules are also posted on the Intranet.
| Dose | Dose | Interval* | |
| Primary 2-dose series | 0.3 mL | 21 days between dose #1 and #2 | |
| Pfizer | Additional 3rd dose | 0.3 mL | 28 days after dose #2 – immunocompromised employees only |
| Booster | .3 mL | 6 months after dose #2 | |
| Primary 2-dose series | 0.5 mL | 28 days between dose #1 and #2 | |
| Moderna | Additional 3rd dose | 0.5 mL | 28 days after dose #2 – immunocompromised employees only |
| Booster | 0.25 mL (half dose) | 6 months after dose #2 | |
| Johnson and Johnson | Primary 1 dose | 0.5 mL | |
| Booster | .5 mL | 2 months |
* In all cases wait 90 days to give COVID-19 vaccine after the employee has received monoclonal antibodies for COVID-19. People with COVID-19 who have symptoms should wait to be vaccinated until they have recovered from their illness.
Please note: Per the CDC, COVID-19 vaccine co-administration with Influenza vaccine is recommended; however, the vaccines should be administered in separate upper extremities. People with COVID-19 who have symptoms should wait to be vaccinated until they have recovered from their illness.